Under the agreement, Cabernet consultants will join clinical-development teams at Lilly to assist in applying pharmacogenetics to selected development projects. Financial terms were not disclosed.
Stephen Eck, vice president of translational medicine and pharmacogenomics at Lilly, said: “Pharmacogenetics has come of age. It is one of the tools we increasingly bring to developing tailored therapeutics for better-defined patient groups.
“The experience of Cabernet in applying pharmacogenetics to drug development will supplement Lilly’s in-house capabilities, providing us a flexible resource as we manage the dynamics of our R&D pipeline.”